novo nordisk obesity drug - Search News

Novo Nordisk Shares Fall

Barron's on MSN · 2h

Novo Nordisk is Falling. A Rival Weight-Loss Drug Is on the Way.

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could cost it up to $5.3 billion.U.S.-listed shares of Novo Nordisk were down 5.2%.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 1d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Roche, Zealand Pharma and obesity

Bloomberg · 10h

Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss drugmaker’s effort to get into a hot market dominated by Novo Nordisk A/S and Eli Lilly & Co.

The Wall Street Journal on MSN · 1h

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Reuters on MSN · 5h

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

2hon MSN

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Pharmaceutical Technology22h

Viking strikes $150m deal to secure supply of obesity drug

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results